Natus Sensory has purchased TheraB Medical, a US-based company specialising in neonatal wearable phototherapy devices.

The acquisition aims to extend access to TheraB Medical’s SnugLit device, a wearable that treats neonatal jaundice, and further Natus Sensory’s initiative to deliver comprehensive, family-focused newborn care.

SnugLit provides phototherapy for infants with jaundice. Designed as an infant swaddle, it offers full body coverage in line with American Academy of Pediatrics' guidelines and removes the need for eye protection typically required with conventional phototherapy.

Its portable design allows greater parent interaction and uninterrupted therapy, supporting continuity across various clinical settings.

Its portability makes it suitable for family-centred care models across different healthcare environments.

TheraB Medical CEO Chris Mathia said: “This acquisition validates TheraB’s mission to improve outcomes for infants diagnosed with neonatal jaundice, while Natus Sensory’s global presence in the paediatric community enables broader access to SnugLit’s innovative phototherapy across hospitals and clinical settings.”

Natus Sensory CEO Peter Reimer said: “At Natus Sensory, our vision in newborn care is simple and deeply personal: to help give every single baby the best possible start in life. TheraB Medical’s wearable phototherapy innovation aligns strongly with that vision.

“It complements our existing hospital-based solutions while expanding how and where effective care can be delivered – always grounded in real clinical needs and focused on improving outcomes for newborns and their families.”

TheraB Medical gained US Food and Drug Administration (FDA) clearance for SnugLit last month.

The company is supported by several investors, including BakerBridge Ventures, Angel Investors, Gulf South Angels, and Foster Lane Investments.